Company news
Starpharma Holdings Limited (ASX:SPL) news
Starpharma Holdings Limited news releases on 6ix. Latest, Aug 21, 2018: Annual report and full year financial results
Press releases — page 4
Annual report and full year financial results
August 21, 2018
VivaGel BV NDA advances to next stage of FDA review
July 9, 2018
Starpharma licenses VivaGel BV to Mundipharma for Europe
June 26, 2018
Mundipharma licenses Starpharmas VivaGel BV
May 3, 2018
Appendix 4C - Quarterly Cashflow Report
April 30, 2018
Starpharma completes US New Drug Application for VivaGel BV
April 29, 2018
Starpharma receives $3.7M R&D tax incentive refund
February 21, 2018
Starpharma to commence DEP cabazitaxel phase 1/2 trial
January 31, 2018
VivaGel BV treatment clinical submission under rolling NDA
December 20, 2017
NDA submission for VivaGel BV in the US
November 21, 2017
VivaGel BV granted marketing approval in Australia
October 24, 2017
Starpharma and Peter Mac Cancer Centre awarded DEP Grant
October 9, 2017
AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor
September 28, 2017
DEP docetaxel positive phase 1 results, phase 2 commences
September 22, 2017
Starpharma and Monash awarded STEM Business Fellowships
August 9, 2017
Successful VivaGel Phase 3 results and NDA planned for rBV
August 6, 2017
VivaGel BV phase 3 results timing and commercialisation
July 4, 2017
Starpharma sells Agrochemicals business to Agrium for $35M
June 13, 2017
DEP irinotecan outperforms irinotecan in cancer models
June 5, 2017
AstraZeneca DEP candidate advance triggers milestone to SPL
April 19, 2017
Ansell launches VivaGel condom in Canada
April 11, 2017
VivaGel BV phase 3 trials for prevention of BV completed
March 29, 2017
Shareholder Update January 2017
January 18, 2017
VivaGel BV granted QIDP and Fast Track designation by US FDA
January 11, 2017
Starpharma receives $3.5M R&D tax incentive refund
December 21, 2016
Starpharma signs license for VivaGel Condom in Iran
November 27, 2016
Additional Priostar Glyphosate Patent Allowed in US
October 27, 2016
Enrolment complete for Phase 3 VivaGel BV-R program
October 12, 2016
VivaGel condom receives regulatory approval in Canada
September 13, 2016
New DEP drug delivery program initiated with AstraZeneca
July 28, 2016
Starpharma signs license for a VivaGel condom in China
July 21, 2016
Appendix 4C - Quarterly Cashflow Reoprt
July 13, 2016
Starpharmas DEP eliminates cabazitaxel neutropenia
May 25, 2016
VivaGel active against Zika virus
May 5, 2016
DEP cabazitaxel shows complete, sustained tumour regression
April 4, 2016
Starpharma signs drug delivery license with AstraZeneca
March 30, 2016
Adama Licenses Starpharmas Priostar for Novel 2,4-D
March 16, 2016
Starpharma licences VivaGel BV to Aspen for ANZ
March 3, 2016
Targeted DEP shows sustained superior performance
February 11, 2016
Starpharma raises $1.9M under Share Purchase Plan
February 10, 2016